Pharmacogenomics in Psychiatric Disorders

Lam, Y. W. Francis; Fukui, Naoki; Sugai, Takuro; Watanabe, Junzo; Watanabe, Yuichiro; Suzuki, Yutato; Someya, Toshiyuki

doi:10.1016/b978-0-12-391918-2.00006-8

Cited by 1 publication

(1 citation statement)

References 172 publications

(167 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several SNPs in and around the 5-HTTLPR may affect its expression, including rs25531 G/A which is located upstream of the gene [50]. Subjects with the long (L) allele of the 5-HTTLPR and rs25531-G allele jointly, reduce SCL6A4 expression to about the level of the short allele (S) of the 5-HTTLPR [51]. One small study found an association of L allele carriers with the rs25531A polymorphism had better response to SSRI treatment correlated to serum concentrations [52].…”

Section: Slc6a4 and Serotonin Transportmentioning

confidence: 99%

Pharmacogenetics of Antidepressants, A Review of Significant Genetic Variants in Different Populations

Reyes-Barron¹,

Tonarelli²,

Delozier³

et al. 2017

Clin Depress

View full text Add to dashboard Cite

Major depressive disorder is a highly prevalent disease that is challenging to treat, often requiring medication and dose adjustments. Genetic factors play an important role in psychotropic medication responses. However, the translation of pharmacogenetics findings to clinical recommendations with regards to antidepressant responses is still in its early stages. We reviewed recent primary research articles, meta-analyses, and reviews on the pharmacogenetics of antidepressant treatment for major depressive disorder in different populations. We identified eight genes with likely associations with treatment responses and summarized genetic variants most likely to influence treatment responses. We determined the frequency of these variants in Caucasian, Asian, Hispanic, and African American populations. The genes are related to functions in drug metabolism, transport, signalling, stress response, and neuroplasticity. Clinical recommendations already exist for CYP2D6 and CYP2C19 cytochrome P450 drug metabolism genes. The other genes are: ABCB1 with single nucleotide polymorphisms (SNPs) rs2032583 and rs2235015; FKBP5 with SNPs rs1360780, rs3800373, and rs4713916; GNB3 with SNP rs5443; BDNF with SNP rs6265; HTR2A with SNPs rs7997012 and rs6313; and SLC6A4 with polymorphisms 5-HTTLPR and STin2. There is significant variability of the frequencies of these polymorphisms in the different populations we reviewed. There is also variability in the antidepressant responses between populations carrying the same polymorphism in some cases, indicating a likely polygenic influence. Future studies in the pharmacogenetics of antidepressants would benefit from including more subjects from underrepresented ethnic groups and stratifying results.

show abstract

Section: Slc6a4 and Serotonin Transportmentioning

confidence: 99%